내분비 검사 시장 규모, 점유율 및 동향 분석 보고서 : 검사 유형별, 기술별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Endocrine Testing Market Summary

The global endocrine testing market size was estimated at USD 14.35 billion in 2025 and is projected to reach USD 27.32 billion by 2033, growing at a CAGR of 8.48% from 2026 to 2033. The market is experiencing steady growth driven by the increasing prevalence of diabetes, thyroid disorders, obesity, fertility-related conditions, and other hormone-associated diseases requiring routine diagnostic monitoring.

The endocrine testing industry's growth is further supported by rising adoption of automated immunoassay platforms, expanding preventive healthcare awareness, and the growing integration of advanced hormone-testing technologies across hospitals, commercial laboratories, and ambulatory care centers.

The growth of the global endocrine testing market is primarily driven by the rising burden of metabolic and hormone-related disorders, particularly diabetes, thyroid dysfunction, obesity, reproductive disorders, and adrenal abnormalities. The increasing prevalence of these conditions has significantly expanded routine hormone monitoring across hospitals, commercial laboratories, and ambulatory care settings. Thyroid stimulating hormone (TSH), insulin, cortisol, testosterone, and reproductive hormone tests are witnessing sustained demand as healthcare systems increasingly emphasize early diagnosis and long-term disease management. In parallel, changing lifestyle patterns, aging populations, obesity incidence, and stress-related endocrine disorders are accelerating testing volumes globally. The growing use of endocrine assays in fertility management and women's health has further strengthened demand for testing for estradiol, progesterone, LH, FSH, and prolactin, particularly in urban healthcare systems with rising preventive healthcare awareness.

A major growth catalyst for the market is the rapid expansion of diabetes and obesity management programs, which continue to increase demand for insulin and metabolic hormone testing. Pharmaceutical innovation in GLP-1 therapies and obesity management has also amplified physician focus on endocrine monitoring and metabolic assessment. The increasing chronic disease burden among younger populations also supports the higher testing frequency. For instance, in June 2024, the NHS reported that diabetes cases among individuals under 40 years of age increased from 173,166 in 2022 to 216,440 in 2023, highlighting the accelerating burden of metabolic disorders and the associated rise in endocrine testing requirements. Similarly, in March 2024, Novo Nordisk received FDA approval for Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease, reinforcing the expanding clinical importance of endocrine-linked metabolic management. Such developments are increasing long-term monitoring requirements across endocrine diagnostic laboratories globally.

Technological advancements in hormone testing platforms are also contributing significantly to market expansion. Laboratories are increasingly adopting highly automated immunoassay systems and tandem mass spectrometry technologies to improve analytical sensitivity, turnaround time, and testing throughput. The shift toward precision endocrinology and reproductive diagnostics has increased demand for highly specific hormone assays that support complex clinical decisions. In addition, healthcare providers are expanding reproductive endocrinology testing menus due to increasing infertility treatment volumes and delayed pregnancies in developed and developing markets. Siemens Healthineers launched its Anti-Mullerian Hormone (AMH) Assay in March 2024 as an expansion of its reproductive endocrinology testing portfolio, designed to assist physicians in evaluating ovarian reserve for IVF-related treatment decisions. Such product innovations continue to strengthen advanced endocrine testing capabilities across commercial laboratories and hospital diagnostic centers.

Another key market driver is the increasing integration of connected endocrine monitoring technologies and biomarker-based disease management solutions. While traditional laboratory testing remains central to endocrine diagnostics within the market scope, healthcare providers are increasingly integrating continuous metabolic monitoring with laboratory-based endocrine assessments to support long-term disease management. Strategic collaborations between diagnostics manufacturers and diabetes management companies are accelerating ecosystem expansion across endocrine-related care pathways. Furthermore, growing investment in hormone-monitoring technologies and biomarker-driven diagnostics is expected to support innovation across the fertility, thyroid, and metabolic testing segments over the forecast period.

Global Endocrine Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global endocrine testing market report based on test type, end-use, technology, and region:

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Thyroid Stimulating Hormone (TSH) Test
• Insulin Test
• Testosterone Test
• Cortisol Test
• Human Chorionic Gonadotropin (hCG) Hormone Test
• Follicle Stimulating Hormone (FSH) Test
• Luteinizing Hormone (LH) Test
• Estradiol (E2) Test
• Progesterone Test
• Prolactin Test
• Dehydroepiandrosterone Sulfate (DHEAS) Test
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay
• Tandem Mass Spectrometry
• Monoclonal & Polyclonal Antibody Technologies
• Clinical Chemistry
• Sensor Technology
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital
• Commercial Laboratory
• Ambulatory Care Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Endocrine Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Test Type Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Endocrine Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Test Type Snapshot
• 2.3. Technology Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Endocrine Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Prevalence of Hormonal and Metabolic Disorders
  • 3.4.2. Growing Adoption of Automated Immunoassay and Molecular Diagnostic Technologies
  • 3.4.3. Increasing Focus on Preventive Healthcare and Routine Health Screening
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost of Advanced Endocrine Diagnostic Technologies
  • 3.5.2. Regulatory and Standardization Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Endocrine Testing Market: Test Type Estimates & Trend Analysis

• 4.1. Global Endocrine Testing Market: Test Type Dashboard
• 4.2. Global Endocrine Testing Market: Test Type Movement Analysis
• 4.3. Global Endocrine Testing Market By Test Type, Revenue
• 4.4. Thyroid Stimulating Hormone (TSH) Test
  • 4.4.1. Thyroid Stimulating Hormone (TSH) Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Insulin Test
  • 4.5.1. Insulin Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Testosterone Test
  • 4.6.1. Testosterone Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Cortisol Test
  • 4.7.1. Cortisol Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 4.8.1. Human Chorionic Gonadotropin (hCG) Hormone Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.9. Follicle Stimulating Hormone (FSH) Test
  • 4.9.1. Follicle Stimulating Hormone (FSH) Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.10. Luteinizing Hormone (LH) Test
  • 4.10.1. Luteinizing Hormone (LH) Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.11. Estradiol (E2) Test
  • 4.11.1. Estradiol (E2) Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.12. Progesterone Test
  • 4.12.1. Progesterone Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.13. Prolactin Test
  • 4.13.1. Prolactin Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.14. Dehydroepiandrosterone Sulfate (DHEAS) Test
  • 4.14.1. Dehydroepiandrosterone Sulfate (DHEAS) Test market estimates and forecasts 2021 to 2033 (USD Million)
• 4.15. Others
  • 4.15.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Endocrine Testing Market: Technology Estimates & Trend Analysis

• 5.1. Global Endocrine Testing Market: End Use Dashboard
• 5.2. Global Endocrine Testing Market: End Use Movement Analysis
• 5.3. Global Endocrine Testing Market by End Use, Revenue
• 5.4. Immunoassay
  • 5.4.1. Immunoassay market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Tandem Mass Spectrometry
  • 5.5.1. Tandem Mass Spectrometry market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Monoclonal & Polyclonal Antibody Technologies
  • 5.6.1. Monoclonal & Polyclonal Antibody Technologies market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Clinical Chemistry
  • 5.7.1. Clinical Chemistry market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Sensor Technology
  • 5.8.1. Sensor Technology market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Endocrine Testing Market: End Use Estimates & Trend Analysis

• 6.1. Global Endocrine Testing Market: Technology Dashboard
• 6.2. Global Endocrine Testing Market: Technology Movement Analysis
• 6.3. Global Endocrine Testing Market by Technology, Revenue
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Commercial Laboratories
  • 6.5.1. Commercial Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Ambulatory Care Centers
  • 6.6.1. Ambulatory Care Centers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Endocrine Testing Market: Regional Estimates & Trend Analysis by End Use Test Type, Technology, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Abbott Laboratories
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. End Use benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. AB Sciex
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. End Use benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Agilent Technologies Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. End Use benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. bioMerieux SA
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. End Use benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Bio-Rad Laboratories Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. End Use benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. DiaSorin S.p.A.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. End Use benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. F. Hoffmann-La Roche Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. End Use benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Laboratory Corporation of America Holdings
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. End Use benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Quest Diagnostics Incorporated
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. End Use benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Ortho Clinical Diagnostics
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. End Use benchmarking
    • 8.3.13.4. Strategic initiatives